Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

February 1, 2024

https://www.globenewswire.com/news-release/2024/02/01/2822037/0/en/Oncternal-Therapeutics-Reports-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science.

Read more at globenewswire.com

Related news for (ONCT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.